MediWound Ltd. (MDWD) Stock Rating Lowered by Zacks Investment Research
Zacks Investment Research cut shares of MediWound Ltd. (NASDAQ:MDWD) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.
According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
Several other analysts have also recently commented on the stock. SunTrust Banks, Inc. restated a buy rating on shares of MediWound in a research note on Monday, June 26th. Aegis restated a buy rating and issued a $11.00 target price on shares of MediWound in a research note on Thursday, May 25th. Finally, Oppenheimer Holdings, Inc. set a $10.00 target price on shares of MediWound and gave the stock a buy rating in a research note on Monday, May 8th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. MediWound presently has a consensus rating of Buy and a consensus price target of $10.19.
Shares of MediWound (MDWD) traded up 0.72% during trading on Tuesday, hitting $7.00. 14,208 shares of the stock were exchanged. The stock’s 50 day moving average price is $6.96 and its 200-day moving average price is $6.41. The company’s market cap is $153.51 million. MediWound has a one year low of $4.25 and a one year high of $8.58.
MediWound (NASDAQ:MDWD) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The firm had revenue of $0.69 million during the quarter, compared to analyst estimates of $0.69 million. During the same quarter last year, the business posted ($0.34) EPS. The firm’s revenue was up 93.8% on a year-over-year basis. On average, analysts predict that MediWound will post ($0.82) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/09/mediwound-ltd-mdwd-stock-rating-lowered-by-zacks-investment-research.html.
Several institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in shares of MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 7,900 shares in the last quarter. Institutional investors and hedge funds own 27.32% of the company’s stock.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.